Zeyad Khalaf Starts a New Position as US Medical Lead, Haematology Pipeline at GSK
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Zeyad Khalaf Starts a New Position as US Medical Lead, Haematology Pipeline at GSK / Ali Çimen, Amy Kemner, cancer, GSK, OncoDaily, Oncology, Zeyad Khalaf
Directly affected
- GSK Gsk-6.8% 8d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Gsk belongs to, so it often moves with news about it.
- NVS Novartis AG+1.5% 15d
Novartis AG is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+12.6% 30d
AstraZeneca is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S-7.3% 30d
Novo Nordisk A/S is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
- SNY Sanofi
Sanofi is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
- ROIV Roivant Sciences+3.3% 11d
Roivant Sciences is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| GSK | +0.04% | +1.60% | base | +4.94% | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | +2.81% | after close | after close | after close |
| NVS | -1.99% | +0.99% | base | +3.33% | after close | after close | after close |
| AZN | -7.81% | +1.49% | base | +2.74% | after close | after close | after close |
| NVO | -4.80% | -0.53% | base | +6.20% | after close | after close | after close |
| SNY | -6.81% | -2.11% | base | +4.53% | after close | after close | after close |
| ROIV | +2.87% | +2.36% | base | +5.95% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Zeyad Khalaf Starts a New Position as US Medical Lead, Haematology Pipeline at GSK Oncodaily
Source: Oncodaily
Energy
| Company | When | Move | Status |
|---|---|---|---|
| AZN | that day | +2.74% | still updating |
| AZN | three days earlier | +1.49% | final price |
| AZN | five days earlier | -7.81% | final price |
| GSK | that day | +4.94% | still updating |
| GSK | three days earlier | +1.60% | final price |
| GSK | five days earlier | +0.04% | final price |
| NVO | that day | +6.20% | still updating |
| NVO | three days earlier | -0.53% | final price |
| NVO | five days earlier | -4.80% | final price |
| NVS | that day | +3.33% | still updating |
| NVS | three days earlier | +0.99% | final price |
| NVS | five days earlier | -1.99% | final price |
| ROIV | that day | +5.95% | still updating |
| ROIV | three days earlier | +2.36% | final price |
| ROIV | five days earlier | +2.87% | final price |
| SNY | that day | +4.53% | still updating |
| SNY | three days earlier | -2.11% | final price |
| SNY | five days earlier | -6.81% | final price |
| XLV | that day | +2.81% | still updating |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 69 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 55 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 65 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 70 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid the energy case looks
12 out of 100Price not final
“Zeyad Khalaf Starts a New Position as US Medical Lead, Haematology Pipeline at GSK” scores 12 out of 100. The score uses 1 sources. The price is not final yet.